Comments

Biomarin Pharmaceutical

BMRNNASDAQ
Logo brought to you by Benzinga Data
PerksBuyCompare Brokers
PerksBuyCompare Brokers
$71.47
0.330.46%
Last update: 10:30 AM
15 minutes delayed
Biomarin Pharmaceutical (BMRN) ForecastNewsEarnings

Guidance

DividendsAnalyst RatingsInsider TradesGovernment TradesShort Interest

Biomarin Pharmaceutical (NASDAQ:BMRN) Stock, Guidance And Forecast

Companies issue guidance, or expectations of future EPS and revenue, so investors have a sense of how much money a company will make in a future period.

Data brought to you by Benzinga APIs

FAQ

Q

What is the most recent guidance for Biomarin Pharmaceutical (BMRN)?

A

The most recent guidance for Biomarin Pharmaceutical (BMRN) was reported on September 4, 2024 for the full year 2024. The company provided earnings per share guidance in the range of $3.10 to $3.25, compared to the estimated EPS of $2.04. Additionally, Biomarin Pharmaceutical forecasted revenue between $2.75B and $2.83B for the quarter.

Browse guidance and forecast on all stocks.

People Also Watch